February 23, 2018 2:37 PM ET


Company Overview of XW Laboratories Inc.

Company Overview

XW Laboratories Inc., a biopharmaceutical company, focuses on developing a portfolio of internally discovered product candidates for the treatment of neurological disorders. The company focuses on developing a series of new CNS drugs that exhibit advantages leading to improved patients' compliance/convenience and/or lowered toxicity profile during drug treatment. Its platforms include Prodrug and Functional Group Switch that allow for quick paths to identify novel candidates by reducing the development cost/time to achieve clinical proof of concept. The company primarily focuses on the China market. It also serves foreign markets via collaboration with other companies. The company is based i...

5th Floor

Building C4 East

No. 666 Gaoxin Road

East Lake Hi-tech Development Zone

Wuhan,  430079



86 27 8763 6577


86 27 8763 5577

Key Executives for XW Laboratories Inc.

XW Laboratories Inc. does not have any Key Executives recorded.

XW Laboratories Inc. Key Developments

XW Laboratories Inc. Announces an Exclusive Licensing Agreement with the University of Pittsburgh to Develop Novel Mitochondria-Targeting Compounds

XW Laboratories Inc. announced an exclusive licensing agreement with the University of Pittsburgh to further commercialize a class of novel compounds based on pioneering mitochondria targeted bis-nitroxide technology developed in the laboratory of Professor Peter Wipf. Mitochondria control energetics, metabolic pathways, stress response and cell death, and are central to many human diseases. Over the past decade, the Wipf lab has played a major role in designing small molecule therapeutics that regulate mitochondrial processes and manage lipid membrane composition. The novel mitochondria targeted bis-nitroxide compounds licensed by XW Labs present a unique opportunity for the company to develop new therapies for a broad range of possible indications in the Central Nervous System (CNS) and oncology. Professor Wipf and his research group have developed mitochondrial targeted proof-of-concept compounds that have demonstrated efficacy in animal disease models such as Huntington's Disease and Traumatic Brain Injury. Their research findings have been published in high-profile journals including Nature Neuroscience and Cell Reports. In the two and half years since its foundation, XW Labs has established a diversified portfolio in the CNS area. The company's program, which is currently going through pre-clinical toxicology studies, features an internally developed novel prodrug compound for two CNS indications. Phase 1 clinical trials for this program are expected to be launched in the second half of 2017.

XW Laboratories Inc. Presents at ChinaBio Partnering Forum 2016, May-18-2016

XW Laboratories Inc. Presents at ChinaBio Partnering Forum 2016, May-18-2016 . Venue: Suzhou, China.

Recent Private Companies Transactions

Private Placement
September 20, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact XW Laboratories Inc., please visit xwlabs.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.